GlassScriptPhysician profile
Kyle Kelly
NPI 1457948804
$6,651.76
in general payments reported to CMS, 2019-2025
25 companies · $2,775 in 2025
The $2,775 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,454 · 2024: $2,423 · 2025: $2,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,493 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,493.27 |
| Education | $158.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $872.89 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $810.11 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Abbvie INC. | $764.42 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $672.44 | 2023-2025 | Sotyktu |
| Incyte Corporation | $483.36 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $457.79 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $455.67 | 2023-2025 | Ilumya, Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $405.26 | 2023-2024 | Vtama |
| Ucb, INC. | $355.62 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $289.48 | 2023-2025 | |
| Pfizer INC. | $167.93 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $148.49 | 2024-2025 | |
| Organon LLC | $139.93 | 2025 | Vtama, Nexplanon |
| Amgen INC. | $97.29 | 2024-2025 | Otezla, Otezla |
| Ani Pharmaceuticals, INC. | $96.89 | 2024 | Purified Cortrophin Gel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.96 | 2023-2025 | Spevigo |
| Leo Pharma INC. | $84.76 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $73.59 | 2024-2025 | Nemluvio |
| Genentech USA, INC. | $39.97 | 2023-2024 | Xolair |
| Lnhc, INC | $37.25 | 2025 | Zelsuvmi |
| Getinge USA Sales, LLC | $35.67 | 2025 | Vasoview Hemopro 2 |
| Arcutis Biotherapeutics, INC. | $21.77 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.67 | 2025 | Siliq, Jublia, Cabtreo |
| Botanix Sb INC | $15.88 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $13.67 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.